Opaleye Management’s Aevi Genomic Medicine Inc GNMX Stock Holding History

Opaleye Management’s Portfolio GNMX Stock Details GNMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-1,070,000	Closed	-$1.99M	–	53
2017 Q1	$1.99M	Sell	1,070,000 -430,000	-29%	-$1.95M	0.99%	30
2016 Q4	$7.77M	Sell	1,500,000 -300,000	-17%	-$1.58M	4.58%	4
2016 Q3	$10M	Sell	1,800,000 -150,000	-8%	-$855K	5.25%	4
2016 Q2	$10.8M	Buy	1,950,000 +392,300	+25%	+$2.06M	7.23%	2
2016 Q1	$6.85M	Buy	1,557,700 +167,700	+12%	+$690K	4.27%	6
2015 Q4	$8.37M	Buy	1,390,000 +331,600	+31%	+$2.25M	3.5%	5
2015 Q3	$8.28M	Buy	1,058,400 +8,400	+0.8%	+$65.1K	4.07%	5
2015 Q2	$6.44M	Buy	1,050,000 +200,000	+24%	+$1.55M	2.56%	18
2015 Q1	$6.85M	Hold	850,000	–	–	3.18%	10
2014 Q4	$4.3M	Buy	+850,000	New	+$4.2M	2.17%	18

Other funds holding GNMX

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return

Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return

ECM

Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return

Opaleye Management's GNMX Position: Q2 2017 in Review

Opaleye Management sold out of Aevi Genomic Medicine Inc (GNMX) in Q2 2017, closing a stake of 1,070,000 shares — an estimated $1.99M sold.

Opaleye Management first reported a position in GNMX in Q4 2014 and held it in 10 quarters. The position peaked at $10.8M in Q2 2016. 51 funds tracked by Wall St. Rank hold GNMX as of Q2 2017.

Opaleye Management reported no remaining Aevi Genomic Medicine Inc position as of Q2 2017 after selling out during the quarter.
Opaleye Management sold 1,070,000 Aevi Genomic Medicine Inc shares in Q2 2017, an estimated $1.99M.
Opaleye Management first reported a position in Aevi Genomic Medicine Inc in Q4 2014 and held it in 10 quarters.
Opaleye Management's Aevi Genomic Medicine Inc position peaked at $10.8M in Q2 2016.
51 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q2 2017.

Based on Opaleye Management's 13F filing for Q2 2017, filed 14 Aug 2017.